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Abstract
Background: Osteoarthritis (OA) represents a significant burden to societies, as it affects quality of life, performance
and poses a large healthcare cost. We aimed to describe the use of a single intra-articular (IA) injection of an
autologous platelet therapy in the management of osteoarthritis (OA) in a naturally occurring canine model.
Methods: Fifteen police working dogs with bilateral hip OA were treated with 3 ml of platelet concentrate per hip
joint, produced with the V-PET kit. Response to treatment was measured by the Canine Brief Pain Inventory (CBPI,
divided in pain interference score – PIS, and Pain Severity Score - PSS), Liverpool Osteoarthritis in Dogs (LOAD),
Canine Orthopedic Index (COI, divided in four dimensions: function, gait, stiffness and quality of life - QOL) and the
Hudson Visual Analogue Scale (HVAS). Seven different time points were considered: T0 (before treatment), T1 (after
15 days), T2, T3, T4, T5 and T6 (after 1, 2, 3, 4 and 5 months respectively). Results from each evaluation moment
were compared with T0 with a Paired Samples T-Test, and a p < 0.05 was set.
Results: Significant differences were observed at T1 (p < 0.01 for HVAS, PSS, COI, Gait and QOL; p = 0.01 for PIS; p =
0.02 for Function; and p < 0.05 for Stiffness), T2 (p < 0.01 for PSS, PIS and Gait; p = 0.01 for COI; p = 0.02 for HVAS,
Function and QOL; and p = 0.04 for Stiffness), T3 (p < 0.01 for HVAS, PSS, PIS, Function and Gait; p = 0.01 for COI; and
p = 0.02 for QOL), T4 (p < 0.01 for PSS; p = 0.03 for PIS and Gait), T5 (p < 0.01 for COI, Function and Gait; p = 0.03 for
PSS, PIS and Stiffness), T6 (p < 0.01 for PSS, Function and Gait; p = 0.04 for PIS; p < 0.05 for COI) and T7 (p < 0.01 for
PSS, Function and Gait; p = 0.01 for COI; and p < 0.05 for PIS).
Conclusions: Autologous platelet therapy was used without apparent harm in the subjects. A single administration
produced significant improvements, which lasted several months, and therefore warrants further study.
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Background
Osteoarthritis (OA) represents a significant burden to
societies, as it affects quality of life, performance and
poses a large healthcare cost [1]. It is also the most
prevalent musculoskeletal disease in dogs, with an ex-
pected increase, due to a simultaneous increase in life
expectancy and obesity [2]. For these reasons, it raises
major welfare challenges and concern [3]. Translational
research is a critical step towards understanding the
long-term effects of OA, and animal models provide
relevant ways to study the natural history and response
to treatment [4]. Canine OA models have the advantages
of being anatomically, biochemically, genomically and
molecularly similar to humans, with close clinical pro-
gression and response to treatment. These naturally oc-
curring models may better reflect the complex genetic,
environmental, temporal and physiological influences
present in humans, being the closest to a gold standard
[4–9]. Therefore, exploring spontaneous OA in dogs
under the One Medicine initiative can help improve the
health and well-being of both humans and dogs [9, 10].
Pain and functional ability are important parameters
in the evaluation of OA treatment efficacy [11]. The gold
standard for the evaluation of lameness is through gait
analysis [12] but this equipment is often confined to re-
search facilities [9]. Several clinical metrology instru-
ments (CMI) have been developed in order to measure
outcome assessments, which for dogs are normally com-
pleted by a proxy. In human medicine, they are a stand-
ard, validated and accepted method for measuring
chronic pain, and have formed an important part of the
patient clinical assessment for over 30 years [13, 14].
The best ones developed for dogs, and that have been
reported to have criterion validity, are the Canine Brief
Pain Inventory (CBPI) and the Liverpool Osteoarthritis
in Dogs (LOAD) [9, 14–16]. The CBPI is divided in two
sections, a pain severity score (PSS), that assesses the
magnitude of the animal pain, and a pain interference
score (PIS), that assesses the degree in which pain affects
daily activities [17]. The Canine Orthopaedic Index
(COI) was developed to assess four domains in dogs
with OA: stiffness, gait, function and quality of life
(QOL). It has been shown to have excellent reliability
and validity, and has been used to evaluate working dogs
[18, 19]. Visual Analogue Scales are one of the tech-
niques used to score pain and assess its severity, allow-
ing the comparison of analgesic protocols. The Hudson
Visual Analogue Scale (HVAS) has been deemed as re-
peatable and valid to assess the degree of mild to moder-
ate lameness in dogs, compared with force plate analysis
as a criterion-referenced standard [20].
Autologous platelets are a regenerative treatment modality
for OA, used with the aim to stimulate the natural healing
cascade and regeneration of tissues by a supraphysiologic
release of platelet derived factors directly at the treat-
ment site, without the risk of immune rejection or dis-
ease transmission [21–23]. Growth factors affect nearly
every biological process [24] and, in platelets concen-
trates, insulin-like growth factor (IGF-1), transforming
growth factor-β (TGF-β), platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (b-FGF), signal cells to
proliferate and influence their maturation, differenti-
ation and tissue repair [25, 26]. Growth factors can be
obtained from other sources, such as autologous condi-
tioned plasma, and are able to reduce pain and lame-
ness scores, and increase weight bearing when injected
into OA joints [27–29]. In dogs, a single intra-articular
(IA) PRP injection has resulted in clinical improve-
ments for 12 weeks, in some cases without progression
of radiographic signs [27, 30, 31]. Through this period,
radiographic scores were the same as assigned before
treatment [30]. Multiple injections protocols have also
been described, providing improvements in ROM, pain,
lameness and kinetics. Authors associated this response
to treatment to an anti-inflammatory activity of PRP ra-
ther than any effect on tissue anabolism or catabolism
[32]. It has also been used as a part of surgical proto-
cols, leading to a significant improvement in gait per-
formance in the postoperative period [31, 33]. V-PET is
a platelet concentrate as well as conditioned plasma,
which contain many autologous anti-inflammatory me-
diators and growth factors, reported to reduce pain and
lameness scores and increase weight bearing in dogs
with OA [27, 28].
The objective of this report is to describe the use of the
platelet concentrate V-PET in the management of OA in
a naturally occurring canine model. We hypothesize that a
single IA administration of platelet concentrate can reduce
pain scores in police working dogs with naturally occur-
ring hip OA for a long period of time.
Methods
The sample comprised animals selected from the popu-
lation of police working dogs of the Guarda Nacional
Republicana (Portuguese Gendarmerie Canine Unit). Se-
lection was made by the assisting veterinarian, based on
the dog’s history, trainer complaints, physical and radio-
graphic findings consistent with bilateral naturally oc-
curring mild and moderate hip OA, classified according
to the Orthopedic Foundation for Animals scoring. Ani-
mals with other illnesses or under any other treatment
were not included in the study, and were ruled out
through physical examination, complete blood count
and serum chemistry profile. Written, informed consent
was obtained for all animals.
The animals were placed under light sedation using
medetomidine (0.01 mg/kg) and buthorphanol (0.1 mg/
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kg), both given intravenously, and then positioned in lat-
eral recumbency with the affected joint uppermost. A
small window of 4x4cm area surrounding the greater
trochanter was clipped and aseptically prepared. The
limb was then placed parallel to the table surface and in
a neutral position by an assistant, and the clinician (the
same in all procedures) inserted a 21-gauge with 2.5″
length needle, just dorsal to the greater trochanter and
perpendicular to the long axis of the limb [34]. Confirm-
ation of correct needle placement was obtained through
the collection of synovial fluid. All animals received 3ml
of platelet concentrate per hip joint, prepared with the
commercially available V-PET kit (PALL Corporation),
according to the manufacturer’s instructions. Fifty-five
milliliters of whole blood were collected from the jugular
vein of the patient, and then introduced into the pro-
vided closed system. The blood then flowed by action of
gravity through the filter, where platelets where concen-
trated. The final product was collected using the pro-
vided syringe. After treatment, animals were rested for 3
consecutive days and resumed their normal activity over
a period of 5 days. Signs of exacerbated pain, persistent
stiffness of gait and changes in posture exhibited by the
dogs, were evaluated by the veterinarian on the days 1
and 3 after the IA procedure. If no complaints were reg-
istered, the animal could resume its normal activity [35,
36].
Response to treatment, as measured by the CBPI
(Additional file 1), COI (Additional file 2), LOAD (Add-
itional file 3) and HVAS (Additional file 4) was evaluated
before treatment (T0), after 15 days (T1) and 1 (T2), 2
(T3), 3 (T4), 4 (T5), 5 (T6) and 6 (T7) months after ini-
tial treatment. These were completed by the trainers,
who were unaware of which treatment the animal re-
ceived, and after receiving the published instructions for
each for them. Normality was assessed with a Shapiro-
Wilk test and each instant was compared with T0 with a
Paired Samples T-Test. All results were analyzed with
IBM SPSS Statistics version 20 and a significance level of
p < 0.05 was set.
Results
All animals enrolled were followed during a 6-month
evaluation period. The sample included 15 working dogs
(N = 15) of both genders (8 females and 7 males), with a
mean age of 7 ± 2.4 years old and body weight of 31.1 ±
4.57 kg. Four breeds were represented: German Shep-
herd Dogs (n = 10), Labrador Retriever (n = 3), Belgian
Malinois Shepherd Dogs (n = 1) and Catch Dog of São
Miguel (n = 1). These were use of force, product and hu-
man scent dogs in active work at the time of treatment
and during the follow up period, and where in similar
kennels of the Portuguese Gendarmerie Canine Unit.
Each animal received an average total solution volume
of 6 ml of platelet was produced with V-PET, divided in
3 ml per hip joint. Increased lameness after the IA ad-
ministration was observed in four dogs, which was spon-
taneously resolved within 48 h.
When comparing results between each time moment
and T0, significant differences were observed in all mo-
ments and with different CMIs. With HVAS, significant
improvements were observed at T1 (p < 0.01), T2 (p =
0.02) and T3 (p < 0.01). When considering individual re-
sults, improved results were observed in 12 animals at
T1 (80%), 11 at T2 (73.3%), 14 at T3 (93.3%), 9 at T4-T6
(60%) and 8 at T7 (53.3%).
With CBPI, significant differences were observed at T1
(p < 0.01 for PSS and p = 0.01 for PIS), T2 (p < 0.01 for
PSS and PIS), T3 (p < 0.01 for PSS and PIS), T4 (p < 0.01
for PSS and p = 0.03 for PIS), T5 (p = 0.03 for PSS and
PIS), T6 (p < 0.01 for PSS and p = 0.04 for PIS) and T7
(p < 0.01 for PSS and p < 0.05 for PIS). Evolution of PSS
and PIS scores can be observed in Fig. 1. Individual
treatment success, as measured by the CBPI, has been
defined as a reduction of ≥1 in PSS and ≥ 2 in PIS [37].
Treatment was successful in reducing PSS in 8 animals
at T1 (53.3%), 11 at T2 (73.3%), 10 at T3 (66.7%), 9 at
T4 (60%) and 8 at T5-T7 (53.4%). In addition, scores im-
proved for 10 animals at T1 (66.7%), 12 at T2 (80%), 11
at T3 (73.3%), 10 at T4 (66.7%), 12 at T5 (80%) and 11
at T6-T7 (73.3%). Considering PIS, treatment was a suc-
cess in 4 animals at T1 (26.7%), 5 at T2 (33.3%), 4 at T3
(26.7%), 3 at T4-T5 and T7 (20%,) and 4 at T6 (26.7%).
Treatment also improved scores for 10 animals at T1
(66.7%), 11 at T2-T3 (73.3%), 9 at T4 (60%), 10 at T5
(66.7%) and 8 at T6-T7 (53.3%).
With COI, significant differences were observed at T1
(p < 0.01 for COI, Gait and QOL, p = 0.02 for Function
and p < 0.05 for Stiffness), T2 (p < 0.01 for Gait, p = 0.01
for COI, p = 0.02 for Function and QOL, and p = 0.04
for Stiffness), T3 (p < 0.01 for Function and Gait, p =
0.01 for COI, and p = 0.02 for QOL), T4 (p = 0.03 for
Gait), T5 (p < 0.01 for COI, Function and Gait, and p =
0.03 for Stiffness), T6 (p < 0.01 for Function and Gait
and p < 0.05 for COI) and T7 (p < 0.01 for Function and
Gait and p = 0.01 for COI). Evolution of COI scores can
be observed in Fig. 2. When considering individual re-
sults, an improvement was observed in all dimensions in
all evaluation points. Regarding stiffness, 7 animals re-
corded better scores at T1 (46.7%), 6 at T2-T4 (40%)
and 7 at T5-T7 (46.7%). Function scores improved in 6
animals at T1-T2 (40%), 8 at T3-T4 (53.3%), 11 at T5
(73.3%), 9 at T6 (60%) and 8 at T7 (53.3%). Gait scores
also improved in a large majority of animals, with better
results when comparing to baseline being registered in
13 animals at T1 (86.7%) at T1, 11 at T2 (73.3%), 10 at
T3 (66.7%), 9 at T4 (60%) and 10 at T5-T7 (66.7%). Re-
garding QOL, 11 animals recorded better scores at T1
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(73.3%), 7 at T2 (46.7%), 9 at T3 (60%), 7 at T4-T5
(46.7%) and 6 at T6-T7 (40%). Several animals also
showed better overall COI scores, namely 13 animals re-
corded better scores at T1 (86.7%), 10 at T2 (66.7%), 11
at T3 (73.3%), 10 at T4-T6 (66.7%) and 11 at T7 (73.3%).
No significant differences were registered in the LOAD
scores when comparing each moment with T0. When
considering individual results, an improvement in results
was observed in 8 animals at T1 (53.3%), 10 at T2
(66.7%), 11 at T3 (73.3%), 12 at T4 (80%), 11 at T5
(73.3%) and 10 at T6-T7 (66.7%).
Discussion
OA is a common, incurable condition that, despite ex-
tensive research, still has limited treatment options avail-
able [10, 38, 39]. Its management is largely palliative,
focussing on the alleviation of symptoms, mainly pain,
and slowing down the progression of the disease [40,
41]. The results show that the animals included in this
sample experienced significant improvements for several
months, as measured with several validated CMI. Since
there is a similarity in neurophysiology paths across
mammals, which indicates that pain is experienced by
Fig. 1 Overall Canine Brief Pain Inventory scores, by section and instant. Box plots represent median, 25th and 75th percentiles, and whiskers
represent 10th and 90th percentiles
Fig. 2 Canine Orthopedic Index scores, by domain and instant. Box plots represent median, 25th and 75th percentiles, and whiskers represent
10th and 90th percentiles
Alves et al. BMC Musculoskeletal Disorders          (2020) 21:127 Page 4 of 7
humans and animals in similar ways [42], it is reasonable
that these results could also be observed in humans.
Previous reports in dogs have described that a single IA
autologous platelet therapy injection has resulted in clin-
ical improvements for 12 weeks, in some cases without
progression of radiographic signs [27, 31]. Our results
show that significant improvements, when compared to
baseline values, are still present at the 6-month evaluation
point, a considerably longer period.
The CBPI survey is often the test of choice to evaluate
chronic pain in veterinary medicine [43, 44]. Treatment
success in OA dogs has been set as a decrease in PSS ≥ 1
and in PIS ≥ 2 [37, 45]. Our results show that IA autolo-
gous platelet therapy was able to significantly reduce
pain levels in dogs, in some cases up to 6 months. Inter-
estingly, it was also able to significantly reduce pain
interference scores, in contrast to other treatment mo-
dalities, such as NSAIDs and nutraceuticals [46].
LOAD was initially developed to assess dog with elbow
OA, but was latter deemed as reliable to asses canine OA
in general [16]. It has shown good reliability, just lower
than peak vertical force generated by a force platform, al-
though both results correlate. CBPI and LOAD results
have a moderate correlation [15, 16]. Even though im-
provements in individual LOAD scores have been ob-
served, no significant differences when considering the
entire sample was considered. A possible explanation to
this fact may be in the nature of the dogs included in the
sample and of the CMI itself. Many of the LOAD items
focus on the level of activity of the dog, its willingness or
ability to exercise. Since the animals included in this study
are working dogs with a very high work drive, it is possible
that the constant willingness of these animals to exercise,
even in cases of overt lameness and pain, may have led to
smaller variations in LOAD scores, when compared to
other CMIs. This may also be true for PIS scores, in
addition to the fact that were low to begin with for many
patients, making it harder to reach a significant reduction.
Considering COI results, it was also interesting to ob-
serve that significant improvements were observed up to
the last evaluation point, specifically in overall score but
also gait and function, two areas particularly affected by
OA. Individual results in all dimensions improved for
most animals, in many cases up to T7.
Visual analogue scales are one of the techniques used to
score pain and assess its severity, allowing to compare dif-
ferent analgesic protocols. The Hudson Visual Analogue
Scale (HVAS) has been deemed as repeatable and valid to
assess the degree of mild to moderate lameness in dogs,
compared with force plate analysis as a criterion-
referenced standard [20]. In this study, significant varia-
tions in HVAS scores were observed, up to T3, even
though individual results improved for a majority of ani-
mals during the 6-month evaluation period.
The obtained results give strength the concept that dif-
ferent components of OA are captured by different CMI
[16], and reinforce the advantage of using more than one
of them when monitoring patients and response to treat-
ment. As a whole, CMIs represent a patient-centred ap-
proach, similar in human and veterinary medicine [10]. It
is still unknown if respondents should be permitted or not
to see previous answers. Previous reports show little dif-
ference has been observed between both approaches, but
allowing responders to see previous answers results in in-
creased treatment effect sizes, which may increase clinical
trial power [47]. In this study, in order to reduce bias,
trainers were not allowed to see previous answers, as it
might influence their responses, particularly with a long
follow-up period.
Increased lameness was observed in four dogs, which
spontaneously resolved within 48 h. This is in contrast
to what is observed with NSAIDs, often the first line of
treatment but with well documented side-effects, par-
ticularly when for long periods [48]. It was, however, in
line with what has been described in humans, were
platelet concentrates can produced local and transient
side-effects, such as injection pain and local inflamma-
tion, that take 2–10 days to resolve [26, 49, 50]. No add-
itional medication was administered to the animals
during the follow up period.
This study presents some limitations, namely the lack of
a control group. Even though the validity of the results is
reinforced by the use of several CMIs, further studies
should include other evaluation method such as Force Plait
Gait Analysis or Stance Analysis. Future studies should also
evaluate the effect that both different cell composition and
administration frequencies have on clinical results.
Conclusions
Autologous platelet therapy showed to be a promising
treatment option for the treatment of OA, as this natur-
ally occurring canine model experienced significant im-
provements, up to the 6-month follow up moment.
Further studies are required, particularly to determine
the clinical effect of different administration frequencies.
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